{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-036854","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.597298+00:00","generated_at":"2026-05-17T22:37:59.712704+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vericel Q2 revenue $63.2M (+20% YoY); net loss narrows to $0.6M; adj. EBITDA up 112% to $13.4M","bullets":["Record Q2 total revenue $63.2M, up 20% YoY; MACI revenue $53.5M, up 21%.","Gross margin improved to 74% (vs 70% Q2 2024); non-GAAP adj. EBITDA $13.4M, 112% growth, margin 21%.","Net loss narrowed to $0.6M ($0.01/sh) from $4.7M loss ($0.10/sh) last year.","Cash & investments $164M, no debt; reaffirmed FY guidance: MACI revenue growth low 20s, gross margin 74%, adj. EBITDA margin 26%.","Received FDA IND clearance for Phase 3 MACI Ankle study; ~600 MACI Arthro surgeons trained."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-036854","json":"https://secwatch.observer/filing/0001628280-25-036854.json","markdown":"https://secwatch.observer/filing/0001628280-25-036854.md","text":"https://secwatch.observer/filing/0001628280-25-036854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828025036854/0001628280-25-036854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828025036854/vcel-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:37:59.712704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}